论文部分内容阅读
本文报道应用人胎肝细胞(FLC)悬液输注治疗7例小儿重症病毒性肝炎,结果6例存活,1例死亡。本组年龄2月～12岁。其中4例为急性重症肝炎(抗-EAV IgM阳性1例,抗-HBc IgM阳性3例);3例为亚急性重症肝炎(抗-HAV IgM阳性2例,抗-HAV IgM及抗-HBc IgM阴性1例),输注前均有不同程度的肝昏迷。作者认为FLC宜用以治疗重症肝炎早、中期病例,可有助于患儿渡过肝衰竭的难关,有利于肝细胞再生。
This article reports the application of human fetal liver cells (FLC) suspension infusion treatment of 7 cases of infantile severe viral hepatitis, the results of 6 cases of survival and 1 case of death. The age of 2 months to 12 years old. Among them, 4 were acute severe hepatitis (anti-EAV IgM positive in 1 and anti-HBc IgM positive in 3); 3 were subacute severe hepatitis (anti-HAV IgM positive in 2, anti-HAV IgM and anti-HBc IgM Negative in 1 case), hepatic coma with different degrees before infusion. The authors believe that FLC should be used to treat severe hepatitis in early and intermediate cases, can help children survive the difficulties of liver failure, is conducive to liver regeneration.